Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/052—Imidazole radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/06—Pyrimidine radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/06—Pyrimidine radicals
  • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/12—Triazine radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

• the present invention relates to nucleic acid labeling compounds. More specifically, the invention provides heterocyclic derivatives containing a detectable moiety. The invention also provides methods of making such heterocyclic derivatives. It further provides methods of attaching the heterocyclic derivatives to a nucleic acid.
• Gene expression in diseased and healthy individuals is oftentimes different and characterizable.
• the ability to monitor gene expression in such cases provides medical professionals with a powerful diagnostic tool. This form of diagnosis is especially important in the area of oncology, where it is thought that the overexpression of an oncogene, or the underexpression of a tumor suppressor gene, results in tumorogenesis. See Mikkelson et al. J. Cell. Biochem. 1991, 46, 3-8.
• the nucleic acid is chemically or biochemically labeled with a detectable moiety and allowed to hybridize with a localized nucleic acid probe of known sequence. The detection of a labeled nucleic acid at the probe position indicates that the targeted gene has been expressed. See International Application Publication Nos.WO 97/27317, WO 92/10588 and WO 97/10365.
• the labeling of a nucleic acid is typically performed by covalently attaching a detectable group (label) to either an internal or terminal position.
• a detectable group label
• scientists have reported a number of detectable nucleotide analogues that have been enzymatically incorporated into an oligo- or polynucleotide. Langer et al, for example, disclosed analogues of dUTP and
• the analogues shown below, possess an allylamine linker arm that is attached to the C-5 position of the pyrimidine ring.
• Petrie et al. disclosed a dATP analogue, 3-[5-[(N-biotinyl-6-aminocaproyl)- aminojpentyl]- 1 -(2-deoxy- ⁇ -D-erythro-pentofuranosyl)- 1 H-pyrazolo [3 , 4-d]pyrimidin-4- amine-5'-triphosphate. Bioconjugate Chem. 1991, 2, 441-446. The analogue, shown below, is modified at the 3-position with a linker arm that is attached to a biotin moiety. Petrie et al. reported that the compound wherein R is biotin is incorporated into DNA by nick translation.
• Prober et al. disclosed a set of four dideoxynucleotides, each containing a succinylfluorescein dye. Science 1987, 238, 336-341.
• the dideoxynucleotides one of which is shown below, were enzymatically incorporated into an oligonucleotide through a template directed extension of a primer.
• the compounds provided for a DNA sequencing method based on gel migration.
• Herrlein et al. disclosed modified nucleoside trisphosphates of the four DNA bases. Helv. Chim. Ada 1994, 11, 586-596. The compounds, one of which is shown below, contain a 3 '-amino group containing radioactive or fluorescent moieties. Herrlein et al. further described the use of the nucleoside analogues as DNA chain terminators.
• Cech et al. disclosed 3'-amino-functionalized nucleoside triphosphates. Collect. Czech. Chem. Commun. 1996, 61, S297-S300. The compounds, one of which is shown below, contain a fluorescein attached to the 3 '-position through an amino linker. Cech et al. proposed that the described functionalized nucleosides would be useful as terminators for DNA sequencing.
• nucleic acid labeling compound that is effectively incorporated into a nucleic acid to provide a readily detectable composition would benefit genetic analysis technologies. It would aid, for example, in the monitoring of gene expression and the detection and screening of mutations and polymorphisms. Such a compound should be suitable for enzymatic incorporation into a nucleic acid. Furthermore, the nucleic acid to which the labeling compound is attached should maintain its ability to bind to a probe, such as a complementary nucleic acid.
• the present invention provides nucleic acid labeling compounds that are capable of being enzymatically incorporated into a nucleic acid.
• the nucleic acids to which the compounds are attached maintain their ability to bind to a complementary nucleic acid sequence.
• A is hydrogen or a functional group that permits the attachment of the nucleic acid labeling compound to a nucleic acid
• T is a template moiety
• H c is a heterocyclic group
• L is a linker moiety
• Q is a detectable moiety
• M is a connecting group, wherein m is an integer ranging from 0 to about 5.
• the nucleic acid labeling compounds are of the following structure:
• A is H or a functional group that permits the attachment of the nucleic acid labeling compound to a nucleic acid
• X is O, S, NRi or CHR 2 , wherein Ri and R 2 are, independently, H, alkyl or aryl
• Y is H, N 3 , F, ORi, SRi or NHRi, wherein Ri is H, alkyl or aryl
• Z is H, N 3 , F or OR], wherein Ri is H, alkyl or aryl
• L is amido alkyl
• Q is a detectable moiety
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• A is H or H 4 O P 3 -;
• X is O;
• Y is H or OR ] ;
• Ri is H, alkyl or aryl;
• Z is H, N 3 , F or OR l5 wherein R] is H, alkyl or aryl;
• L is -C(O)NH(CH ) n NH-, wherein n is an integer ranging from about 2 to aboutlO;
• Y is H or OH; Z is H or OH; L is -C(O)NH(CH 2 ) 4 NH-; Q is biotin; and, M is -CO(CH 2 ) 5 NH, wherein m is 1.
• Y is H or OH; Z is H or OH; L is -C(O)NH(CH 2 ) 4 NH-; Q is 5 -carboxyfluorescein; and, m is 0.
• nucleic acid labeling compounds are of the following structure:
• A is H or a functional group that permits the attachment of the nucleic acid labeling compound to a nucleic acid
• X is O, S, NRi or CHR , wherein Ri and R are, independently, H, alkyl or aryl
• Y is H, N 3 , F, ORi, SRi or NHRi, wherein Rj is H, alkyl or aryl
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl
• L is amino alkyl
• Q is a detectable moiety
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• A is H or H 4 O 9 P 3 -;
• X is O;
• Y is H or ORi, wherein Rj is H, alkyl or aryl;
• Z is H, N 3 , F or ORi, wherein Rj is H, alkyl or aryl;
• L is -NH(CH ) n NH-, wherein n is an integer ranging from about 2 to about 10;
• Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH- wherein m is 1 or 0.
• Y is H or OH;
• Z is H or OH;
• L is -NH(CH 2 ) 4 NH-;
• Q is biotin; and, m is 0.
• Y is H or OH; Z is H or OH; L is -NH(CH 2 ) 4 NH-; Q is 5- carboxyfluorescein; and, m is 0.
• nucleic acid labeling compounds are of the following structure:
• A is H or a functional group that permits the attachment of the nucleic acid labeling compound to a nucleic acid
• X is O, S, NRi or CHR , wherein Rj and R are, independently, H, alkyl or aryl
• Y is H, N 3 , F, ORi, SRi or NHRi, wherein Ri is H, alkyl or aryl
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl
• L is alkynyl alkyl
• Q is a detectable moiety
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• A is H or H 4 O 9 P 3 -;
• X is O;
• Y is H or ORi, wherein Rj is H, alkyl or aryl;
• Z is H, N 3 , F or OR 1 ;
• Ri is H, alkyl or aryl;
• L is -C ⁇ C(CH 2 ) n NH- wherein n is an integer ranging from about 1 to about 10;
• Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH-, wherein m is 1 or 0.
• Y is H or OH; Z is H or OH; L is -C ⁇ CCH 2 NH-; Q is biotin; and, m is 1.
• Y is H or OH; Z is H or OH; L is -C ⁇ CCH 2 NH-; Q is 5- carboxyfluorescein; and, m is 1.
• nucleic acid labeling compounds are of the following structure:
• A is H or a functional group that permits the attachment of the nucleic acid labeling compound to a nucleic acid
• X is O, S, NRi or CHR 2 , wherein R] and R 2 are, independently, H, alkyl or aryl
• Y is H, N 3 , F, ORi, SRi or NHRi, wherein Rj is H, alkyl or aryl
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl; L is amino alkyl; Q is a detectable moiety; and, M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• A is H or H 4 O 9 P 3 -;
• X is O;
• Y is H or OR], wherein Ri is H, alkyl or aryl;
• Z is H, N 3 , F or OR wherein Rj is H, alkyl or aryl;
• L is -NH(CH 2 ) n NH- wherein n is an integer ranging from about 2 to about 10;
• Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH- wherein m is 1 or 0.
• Y is H or OH;
• Z is H or OH;
• L is -NH(CH 2 ) 4 NH-;
• Q is biotin; and
• M is -CO(CH 2 ) 5 NH-, wherein m is 1.
• nucleic acid labeling compounds are of the following structure:
• A is H or a functional group that permits the attachment of the nucleic acid labeling compound to a nucleic acid
• X is O, S, NRi or CHR , wherein Ri and R 2 are, independently, H, alkyl or aryl
• Y is H, N 3 , F, ORj, SRi or NHRi, wherein Ri is H, alkyl or aryl
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl
• L is functionalized alkyl, alkenyl alkyl or alkynyl alkyl
• Q is a detectable moiety
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• A is H or H O 9 P 3 -;
• X is O;
• Y is H or ORj, wherein Ri is H, alkyl or aryl;
• Z is H, N 3 , F or ORi, wherein R] is H, alkyl or aryl;
• L is
• -CH CH(CH ) n NH-, wherein n is an integer ranging from about 1 to about 10; Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH- wherein m is 1 or 0.
• nucleic acid labeling compounds are of the following structure:
• A is H or a functional group that permits the attachment of the nucleic acid labeling compound to a nucleic acid
• X is O, S, NR) or CHR 2 , wherein Ri and R 2 are, independently, H, alkyl or aryl
• Y is H, N 3 , F, ORi, SRj or NHRi, wherein Ri is H, alkyl or aryl
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl
• L is functionalized alkyl, alkenyl alkyl or alkynyl alkyl
• Q is a detectable moiety
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• A is H or H 4 O 9 P 3 -;
• X is O;
• Y is H or OR 1; wherein Rj is H, alkyl or aryl;
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl;
• Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH ⁇ or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH- wherein m is 1 or 0.
• the present invention also provides nucleic acid derivatives produced by coupling a nucleic acid labeling compound with a nucleic acid and hybridization products comprising the nucleic acid derivatives bound to a complementary probe.
• nucleic acid labeling compound used in the coupling is of the following structure:
• A is H or H 4 O 9 P -;
• X is O;
• Y is H or ORi, wherein Ri is H, alkyl or aryl;
• Z is H, N 3 , F or OR], wherein Ri is H, alkyl or aryl;
• L is -C(O)NH(CH 2 ) n NH-, wherein n is an integer ranging from about 2 to aboutlO;
• Q is biotin or a carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH- wherein m is 1 or 0.
• the hybridization product formed from this nucleic acid derivative comprises the nucleic acid derivative bound to a complementary probe.
• the probe is attached to a glass chip.
• nucleic acid labeling compound used in the coupling is of the following structure:
• A is H or H 4 O P -;
• X is O;
• Y is H or ORi, wherein Ri is H, alkyl or aryl;
• Z is H,
• Ri is H, alkyl or aryl
• L is -NH(CH 2 ) n NH-, wherein n is an integer ranging from about 2 to about 10
• Q is biotin or carboxyfluorescein
• M is
• the hybridization product formed from this nucleic acid derivative comprises the nucleic acid derivative bound to a complementary probe.
• the probe is attached to a glass chip.
• the nucleic acid labeling compound used in the coupling is of the following structure:
• A is H or H 4 O P 3 -;
• X is O;
• Y is H or ORi, wherein Ri is H, alkyl or aryl;
• Z is H,
• Ri is H, alkyl or aryl
• L is -C ⁇ C(CH 2 ) n NH-, wherein n is an integer ranging from about 1 to about 10
• Q is biotin or carboxyfluorescein
• M is -CO(CH 2 ) 5 NH- wherein m is 1 or 0.
• the hybridization product formed from this nucleic acid derivative comprises the nucleic acid derivative bound to a complementary probe.
• the probe is attached to a glass chip.
• nucleic acid labeling compound used in the coupling is of the following structure:
• A is H or H 4 O P 3 -;
• X is O;
• Y is H or OR ls wherein Ri is H, alkyl or aryl;
• Z is H,
• Ri is H, alkyl or aryl
• L is -NH(CH ) n NH-, wherein n is an integer ranging from about 2 to about 10
• Q is biotin or carboxyfluorescein
• M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH-, wherein m is 1 or 0.
• the hybridization product formed from this nucleic acid derivative comprises the nucleic acid derivative bound to a complementary probe.
• the probe is attached to a glass chip.
• nucleic acid labeling compound used in the coupling is of the following structure:
• A is H or H O 9 P 3 -;
• X is O;
• Y is H or ORi, wherein Ri is H, alkyl or aryl;
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl;
• Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH- wherein m is 1 or 0.
• the hybridization product formed from this nucleic acid derivative comprises the nucleic acid derivative bound to a complementary probe.
• the probe is attached to a glass chip.
• nucleic acid labeling compound used in the coupling is of the following structure:
• A is H or H 4 O P 3 -;
• X is O;
• Y is H or ORj, wherein Rj is H, alkyl or aryl;
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl;
• Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH- wherein m is 1 or 0.
• the hybridization product formed from this nucleic acid derivative comprises the nucleic acid derivative bound to a complementary probe.
• the probe is attached to a glass chip.
• the present invention also provides methods of synthesizing nucleic acid derivatives by attaching a nucleic acid labeling compound to a nucleic acid. It further provides methods of detecting nucleic acids involving incubating the nucleic acid derivatives with a probe.
• nucleic acid labeling compound attached to the nucleic acid is of the following structure:
• A is H or H 4 O 9 P 3 -;
• X is O;
• Y is H or OR ls wherein Ri is H, alkyl or aryl;
• Z is H, N 3 , F or ORj, wherein Ri is H, alkyl or aryl;
• L is -C(O)NH(CH 2 ) n NH-, wherein n is an integer ranging from about 2 to aboutlO;
• the method of nucleic acid detection using the nucleic acid derivative involves the incubation of the derivative with a probe.
• the probe is attached to a glass chip.
• nucleic acid labeling compound attached to the nucleic acid is of the following structure:
• A is H or H 4 O P 3 -;
• X is O;
• Y is H or ORj, wherein Ri is H, alkyl or aryl;
• Z is H,
• Ri is H, alkyl or aryl
• L is -NH(CH 2 ) n NH-, wherein n is an integer ranging from about 2 to about 10
• Q is biotin or carboxyfluorescein
• M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH-, wherein m is 1 or 0.
• the method of nucleic acid detection using the nucleic acid derivative involves the incubation of the derivative with a probe.
• the probe is attached to a glass chip.
• nucleic acid labeling compound attached to the nucleic acid is of the following structure:
• A is H or H 4 O P -;
• X is O;
• Y is H or ORi, wherein Ri is H, alkyl or aryl;
• Z is H, N 3 , F or ORi, wherein Rj is H, alkyl or aryl;
• Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH- wherein m is 1 or 0.
• the method of nucleic acid detection using the nucleic acid derivative involves the incubation of the derivative with a probe.
• the probe is attached to a glass chip.
• nucleic acid labeling compound attached to the nucleic acid is of the following structure:
• A is H or H O 9 P 3 -;
• X is O;
• Y is H or ORi, wherein Ri is H, alkyl or aryl;
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl;
• L is -NH(CH 2 ) n NH-, wherein n is an integer ranging from about 2 to about 10;
• Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH- wherein m is 1 or 0.
• the method of nucleic acid detection using the nucleic acid derivative involves the incubation of the derivative with a probe.
• the probe is attached to a glass chip.
• the nucleic acid labeling compound attached to the nucleic acid is of the following structure:
• A is H or H 4 O 9 P 3 -;
• X is O;
• Y is H or ORi, wherein Rj is H, alkyl or aryl;
• Z is H, N 3 , F or ORi, wherein Ri is H, alkyl or aryl;
• Q is biotin or carboxyfluorescein; and, M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH- wherein m is 1 or 0.
• the method of nucleic acid detection using the nucleic acid derivative involves the incubation of the derivative with a probe.
• the probe is attached to a glass chip.
• nucleic acid labeling compound attached to the nucleic acid is of the following structure:
• A is H or H 4 O 9 P 3 -;
• X is O;
• Y is H or ORi, wherein Ri is H, alkyl or aryl;
• Z is H, N 3 , F or OR], wherein Rj is H, alkyl or aryl;
• Q is biotin or carboxyfluorescein; and, M is
• the method of nucleic acid detection using the nucleic acid derivative involves the incubation of the derivative with a probe.
• the probe is attached to a glass chip.
• Figure 2 shows a nonlimiting set of heterocyclic groups: 4-aminopyrazolo[3,4- djpyrimidine, pyrazolo[3,4-d]pyrimidine, 1,3-diazole (imidazole), l,2,4-triazine-3-one, l,2,4-triazine-3,5-dione and 5-amino-l,2,4-triazine-3-one.
• Figure 3 shows a synthetic route to fluorescein and biotin labeled l-(2,3-dideoxy-D- glycero-pentafuranosyl)imidazole-4-carboxamide nucleotides.
• Figure 4 shows a synthetic route to C3-labeled 4-aminopyrazolo[3,4-d]pyrimidine ⁇ -D-ribofuranoside triphosphates.
• Figure 5 shows a synthetic route to fluorescein and biotin labeled N6-dideoxy- pyrazolo[3 ,4-d]pyrimidine nucleotides.
• Figure 6 shows a synthetic route to N4-labeled l,2,4-triazine-3-one ⁇ -D- ribofuranoside triphosphates.
• Figure 7 shows a synthetic route to biotin and fluorescein C5-labeled 1 ,2,4-triazine- 3,5-dione riboside triphosphates.
• Figure 8 shows a synthetic route to biotin and fluorescein C5-labeled 5-amino- 1 ,2,4-triazine-3 -one riboside triphosphates.
• Figure 9 shows graphical comparisons of observed hybridization fluorescence intensities using Fluorescein-ddlTP and Fluorescein-ddATP.
• Figure 12 shows a graphical comparison of overall re-sequencing (base-calling) accuracy using Fluorescein-ddlTP and Fluorescein-N6-ddATP labeled targets.
• Alkyl refers to a straight chain, branched or cyclic chemical group containing only carbon and hydrogen. Alkyl groups include, without limitation, ethyl, propyl, butyl, pentyl, cyclopentyl and 2-methylbutyl. Alkyl groups are unsubstituted or substituted with 1 or more substituents (e.g., halogen, alkoxy, amino).
• Aryl refers to a monovalent, unsaturated aromatic carbocyclic group.
• Aryl groups include, without limitation, phenyl, naphthyl, anthryl and biphenyl.
• Aryl groups are unsubstituted or substituted with 1 or more substituents (e.g. halogen, alkoxy, amino).
• amido alkyl refers to a chemical group having the structure -C(O)NR 3 R 4 ⁇ , wherein R is hydrogen, alkyl or aryl, and R is alkyl or aryl.
• the amido alkyl group is of the structure -C(O)NH(CH2) n R 5 -, wherein n is an integer ranging from about 2 to about 10, and R 5 is O, NR ⁇ , or C(O), and wherein R is hydrogen, alkyl or aryl.
• the amido alkyl group is of the structure -C(O)NH(CH 2 ) n N(H)-, wherein n is an integer ranging from about 2 to about 6.
• the amido alkyl group is of the structure -C(O)NH(CH 2 ) 4 N(H)-.
• Alkynyl alkyl refers to a chemical group having the structure -C ⁇ C-R ⁇ , wherein R 4 is alkyl or aryl.
• the alkynyl alkyl group is of the structure -C ⁇ C-(CH2) n R 5 -, wherein n is an integer ranging from 1 to about 10, and R is O, NR 6 or
• the alkynyl alkyl group is of the structure -C- ⁇ C-(CH 2 ) n N(H)-, wherein n is an integer ranging from 1 to about 4. Most preferably, the alkynyl alkyl group is of the structure -C ⁇ C-CH 2 N(H)-.
• alkenyl alkyl refers to a chemical group having the structure -CH ⁇ CH- ⁇ -, wherein R 4 is alkyl or aryl.
• the alkenyl alkyl group is of the structure
• “Functionalized alkyl” refers to a chemical group of the structure -(CH 2 ) n R 7 -, wherein n is an integer ranging from 1 to about 10, and R is O, S, NH or C(O).
• the functionalized alkyl group is of the structure -(CH 2 ) n C(O)-, wherein n is an integer ranging from 1 to about 4. More preferably, the functionalized alkyl group is of the structure -CH 2 C(O)-.
• Alkoxy refers to a chemical group of the structure -O(CH 2 ) n R 8 -, wherein n is an integer ranging from 2 to about 10, and R 8 is O, S, NH or C(O).
• the alkoxy group is of the structure -O(CH 2 ) n C(O)-, wherein n is an integer ranging from 2 to about 4.
• the alkoxy group is of the structure -OCH 2 CH 2 C(O)-.
• Thio refers to a chemical group of the structure -S(CH 2 ) n R 8 -, wherein n is an integer ranging from 2 to about 10, and R 8 is O, S, NH or C(O).
• the thio group is of the structure -S(CH 2 ) n C(O)-, wherein n is an integer ranging from 2 to about 4. More preferably, the thio group is of the structure -SCH 2 CH C(O)-.
• amino alkyl refers to a chemical group having an amino group attached to an alkyl group.
• an amino alkyl is of the structure -NH(CH 2 ) n NH- wherein n is an integer ranging from about 2 to about 10. More preferably it is of the structure -NH(CH 2 )nNH-, wherein n is an integer ranging from about 2 to about 4. Most preferably, the amino alkyl group is of the structure -NH(CH 2 ) 4 NH-.
• Nucleic acid refers to a polymer comprising 2 or more nucleotides and includes single-, double- and triple stranded polymers.
• Nucleotide refers to both naturally occurring and non-naturally occurring compounds and comprises a heterocyclic base, a sugar, and a linking group, preferably a phosphate ester.
• structural groups may be added to the ribosyl or deoxyribosyl unit of the nucleotide, such as a methyl or allyl group at the 2'-O position or a fluoro group that substitutes for the 2'-O group.
• nucleic acid may be substituted or modified, for example with methyl phosphonates or O-methyl phosphates.
• Bases and sugars can also be modified, as is known in the art.
• Nucleic acid for the purposes of this disclosure, also includes “peptide nucleic acids” in which native or modified nucleic acid bases are attached to a polyamide backbone.
• Probe refers to a nucleic acid that can be used to detect, by hybridization, a target nucleic acid.
• the probe is complementary to the target nucleic acid along the entire length of the probe, but hybridization can occur in the presence of one or more base mismatches between probe and target.
• A is hydrogen or a functional group that permits the attachment of the nucleic acid labeling compound to a nucleic acid
• T is a template moiety
• H c is a heterocyclic group
• L is a linker moiety
• Q is a detectable moiety
• M is an connecting group, wherein m is an integer ranging from 0 to about 5.
• the group A is either hydrogen or a functional group that permits the attachment of a nucleic acid labeling compound to a nucleic acid.
• groups include the following: monophosphate; diphosphate; triphosphate (H 4 O 9 P); phosphoramidite ((R 2 N)(R'O)P), wherein R is linear, branched or cyclic alkyl, and R'is a protecting group such as 2-cyanoethyl; and H-phosphonate (HP(O)O-HNR ), wherein R is linear, branched or cyclic alkyl.
• the template moiety (T) is covalently attached to a methylene group (CH 2 ) at one position and a heterocyclic group (H c ) at another position.
• a nonlimiting set of template moieties is shown in FIG. 1, wherein the substituents are defined as follows: X is O, S, NR, or CHR 2 ; Y is H, N 3 , F, OR, , SRi or NHRi ; Z is H, N 3 , F or ORi ; W is O, S or CH 2 ; D is O or S; and, G is O, NH or CH 2 .
• the substituents Ri and R are independent of one another and are H, alkyl or aryl.
• the heterocyclic group (H c ) is a cyclic moiety containing both carbon and a heteroatom.
• Nonlimiting examples of heterocyclic groups contemplated by the present invention are shown in FIG. 2.: 4-aminopyrazolo[3,4-d]pyrimidine; pyrazolo[3,4- d]pyrimidine; 1,3-diazole (imidazole); l,2,4-triazine-3-one; l,2,4-triazine-3,5-dione; and,
• the linker moiety (L) of the nucleic acid labeling compound is covalently bound to the heterocycle (H c ) at one terminal position. It is attached to the detectable moiety (Q) at another terminal position, either directly or through a connecting group (M). It is of a structure that is sterically and electronically suitable for incorporation into a nucleic acid.
• linker moieties include amido alkyl groups, alkynyl alkyl groups, alkenyl alkyl groups, functionalized alkyl groups, alkoxyl groups, thio groups and amino alkyl groups.
• Amido alkyl groups are of the structure -C(O)NR R 4 -, wherein R is hydrogen, alkyl or aryl, and ⁇ is alkyl or aryl.
• the amido alkyl group is preferably of the structure -C(O)NH(CH 2 )nR5-, wherein n is an integer ranging from about 2 to about 10 and R 5 is O,
• the amido alkyl group is of the structure -C(O)NH(CH 2 ) n N(H)-, wherein n is an integer ranging from about 2 to about 6. Most preferably, the amido alkyl group is of the structure -C(O)NH(CH 2 ) 4 N(H)-.
• Alkynyl alkyl groups are of the structure -C ⁇ C-r ⁇ -, wherein R 4 is alkyl or aryl.
• the alkynyl alkyl group is preferably of the structure -C ⁇ C(CH 2 ) n R 5 -, wherein n is an integer ranging from 1 to about 10 and R 5 is O, NR or C(O), and wherein R 6 is hydrogen, alkyl or aryl. More preferably, the alkynyl alkyl group is of the structure -C ⁇ C-(CH 2 ) n N(H)-, wherein n is an integer ranging from 1 to about 4. Most preferably, the alkynyl alkyl group is of the structure -C ⁇ C-CH N(H)-.
• Functionalized alkyl groups are of the structure -(CH 2 ) n R 7 -, wherein n is an integer ranging from 1 to about 10, and R 7 is O, S, NH, or C(O).
• the functionalized alkyl group is preferably of the structure -(CH 2 ) n C(O)-, wherein n is an integer ranging from 1 to about 4. More preferably, the functionalized alkyl group is -CH 2 C(O)-.
• Alkoxy groups are of the structure -O(CH 2 ) n R 8 -, wherein n is an integer ranging from 2 to about 10, and R 8 is O, S, NH, or C(O).
• the alkoxy group is preferably of the structure -O(CH 2 ) n C(O)-, wherein n is an integer ranging from 2 to about 4. More preferably, the alkoxy group is of the structure -OCH 2 CH 2 C(O)-.
• Thio groups are of the structure -S(CH 2 ) n R8-, wherein n is an integer ranging from
• R 8 is O, S, NH, or C(O).
• the thio group is preferably of the structure -S(CH 2 ) n C(O)-, wherein n is an integer ranging from 2 to about 4. More preferably, the thio group is of the structure -SCH 2 CH 2 C(O)-.
• Amino alkyl groups comprise an amino group attached to an alkyl group.
• amino alkyl groups are of the structure -NH(CH 2 ) n NH-, wherein n is an integer ranging from about 2 to about 10.
• the amino alkyl group is more preferably of the structure -NH(CH ) n NH-, wherein n is an integer ranging from about 2 to about 4.
• the amino alkyl group is of the structure -NH(CH 2 ) 4 NH-.
• the detectable moiety (Q) is a chemical group that provides an signal.
• the signal is detectable by any suitable means, including spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. In certain cases, the signal is detectable by 2 or more means.
• the detectable moiety provides the signal either directly or indirectly.
• a direct signal is produced where the labeling group spontaneously emits a signal, or generates a signal upon the introduction of a suitable stimulus.
• Radiolabels such as 3 H, 125 1, 35 S, 14 C or 32 P, and magnetic particles, such as DynabeadsTM, are nonlimiting examples of groups that directly and spontaneously provide a signal.
• Labeling groups that directly provide a signal in the presence of a stimulus include the following nonlimiting examples: colloidal gold (40 - 80 nm diameter), which scatters green light with high efficiency; fluorescent labels, such as fluorescein, texas red, rhodamine, and green fluorescent protein (Molecular Probes, Eugene, Oregon), which absorb and subsequently emit light; chemiluminescent or bioluminescent labels, such as luminol, lophine, acridine salts and luciferins, which are electronically excited as the result of a chemical or biological reaction and subsequently emit light; spin labels, such as vanadium, copper, iron, manganese and nitroxide free radicals, which are detected by electron spin resonance (ESR) spectroscopy; dyes, such as quinoline dyes, triarylmethane dyes and acridine dyes, which absorb specific wavelengths of light; and colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.)
• a detectable moiety provides an indirect signal where it interacts with a second compound that spontaneously emits a signal, or generates a signal upon the introduction of a suitable stimulus.
• Biotin for example, produces a signal by forming a conjugate with streptavidin, which is then detected. See Hybridization With Nucleic Acid Probes. In Laboratory Techniques in Biochemistry and Molecular Biology; Tijssen, P., Ed.; Elsevier: New York, 1993; Vol. 24.
• An enzyme such as horseradish peroxidase or alkaline phosphatase, that is attached to an antibody in a label-antibody-antibody as in an ELISA assay, also produces an indirect signal.
• a preferred detectable moiety is a fluorescent group.
• Flourescent groups typically produce a high signal to noise ratio, thereby providing increased resolution and sensitivity in a detection procedure.
• the fluorescent group absorbs light with a wavelength above about 300 nm, more preferably above about 350 nm, and most preferably above about 400 nm.
• the wavelength of the light emitted by the fluorescent group is preferably above about 310 nm, more preferably above about 360 nm, and most preferably above about 410 nm.
• the fluorescent detectable moiety is selected from a variety of structural classes, including the following nonlimiting examples: 1- and 2-aminonaphthalene, p,p'diaminostilbenes, pyrenes, quaternary phenanthridine salts, 9-aminoacridines, p,p'- diaminobenzophenone imines, anthracenes, oxacarbocyanine, marocyanine, 3- aminoequilenin, perylene, bisbenzoxazole, bis-p-oxazolyl benzene, 1 ,2-benzophenazin, retinol, bis-3-aminopridinium salts, hellebrigenin, tetracycline, sterophenol, benzimidazolyl phenylamine, 2-oxo-3-chromen, indole, xanthen, 7-hydroxycoumarin, phenoxazine, salicylate, strophanthidin, porphyrins,
• fluorescent compounds are suitable for incorporation into the present invention.
• Nonlimiting examples of such compounds include the following: dansyl chloride; fluoresceins, such as 3,6-dihydroxy-9-phenylxanthhydrol; rhodamineisothiocyanate; N-phenyl-l-amino-8-sulfonatonaphthalene; N-phenyl-2-amino-
• 6-sulfonatonaphthanlene 4-acetamido-4-isothiocyanatostilbene-2,2' -disulfonic acid; pyrene-3 -sulfonic acid; 2-toluidinonapththalene-6-sulfonate; N-phenyl, N-methyl 2- aminonaphthalene-6-sulfonate; ethidium bromide; stebrine; auromine-0,2-(9'- anthroyl)palmitate; dansyl phosphatidylethanolamin; N,N'-dioctadecyl oxacarbocy canine; N,N'-dihexyl oxacarbocyanine; merocyanine, 4-(3'-pyrenyl)butryate; d-3-aminodesoxy- equilenin; 12-(9'-anthroyl)stearate; 2-methylanthracene; 9-vinylanthrac
• colloidal gold Another preferred detectable moiety is colloidal gold.
• the colloidal gold particle is typically 40 to 80 nm in diameter.
• the colloidal gold may be attached to a labeling compound in a variety of ways.
• the linker moiety of the nucleic acid labeling compound terminates in a thiol group (-SH), and the thiol group is directly bound to colloidal gold through a dative bond.
• -SH thiol group
• it is attached indirectly, for instance through the interaction between colloidal gold conjugates of antibiotin and a biotinylated labeling compound.
• the detection of the gold labeled compound may be enhanced through the use of a silver enhancement method. See Danscher et al. J.
• the connecting group (M) m may serve to covalently attach the linker group (L) to the detectable moiety (Q). It is of any suitable structure that will not interfere with the function of the labeling compound.
• M groups include the following: -CO(CH 2 ) 5 NH- -CO-, -CO(O)- -CO(NH)-, and -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH-; wherein, m is an integer ranging from 0 to about 5, preferably 0 to about 3.
• nucleic acid labeling compounds of the present invention are of the following structure:
• L is a linker moiety; Q is a detectable moiety; X is O, S, NRi or CHR 2 ; Y is H, N 3 , F, ORi, SRi or NHRi ; Z is H, N 3 , F or ORi; H c is a heterocyclic group; A is H or a functional group that permits the attachment of the nucleic acid label to a nucleic acid; and, M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• the substituents R ⁇ and R 2 are independent of one another and are H, alkyl or aryl.
• the heterocyclic group (H c ) is an imidazole
• the nucleic acid labeling compounds are of the following structure:
• L is a linker moiety
• Q is a detectable moiety
• X is O, S, NR] or CHR 2
• Y is H, N 3 , F, OR], SRi or NHRi
• Z is H, N 3 , F or ORj
• A is H or a functional group that permits the attachment of the nucleic acid label to a nucleic acid
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• the substituents Ri and R are independent of one another and are H, alkyl or aryl.
• heterocyclic group (H c ) is an imidazole and the linking moiety is amido alkyl:
• Y is hydrogen or hydroxyl
• Z is hydrogen or hydroxyl
• R 3 is hydrogen or alkyl
• R 4 is -(CH 2 ) n NH-, wherein n is an integer ranging from about 2 to about 10
• Q is biotin or carboxyfluorescein
• A is hydrogen or H 4 O 9 P -
• M is -CO(CH 2 ) 5 NH- or -CO-, wherein m is 1 or 0.
• Y and Z are hydrogen; R 3 is hydrogen; R 4 is -(CH 2 ) 4 NH-; A is H 4 O 9 P 3 -; and, Q is biotin, wherein M is -CO(CH 2 ) 5 NH- and m is 1, or 5- or 6-carboxyfluorescein, wherein m is 0.
• the heterocyclic group (H c ) is a C3 substituted 4-amino- pyrazolo[3,4-d]pyrimidine, and the nucleic acid labeling compounds are of the following structure:
• L is a linker moiety
• Q is a detectable moiety
• X is O, S, NRi or CHR 2
• Y is H, N 3 , F, ORj, SRi or NHRi
• Z is H, N 3 , F or ORi
• A is H or a functional group that permits the attachment of the nucleic acid label to a nucleic acid
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• the substituents Ri and R 2 are independent of one another and are H, alkyl or aryl.
• the heterocyclic group (H c ) is a C3 substituted 4- aminopyrazolo[3,4-d]pyrimidine and the linking group is an alkynyl alkyl:
• Y is hydrogen or hydroxyl
• Z is hydrogen or hydroxyl
• n is an integer ranging from 1 to about 10
• R 5 is O or NH
• A is hydrogen or H 4 O P 3 -
• Q is biotin or carboxyfluorescein
• M is -CO(CH 2 ) 5 NH-, wherein m is 1 or 0. More preferably, Y and Z are OH; n is 1 ; R 5 is
• heterocyclic group (H c ) is an C4 substituted pyrazolo[3,4-d]pyrimidine, and the nucleic acid labeling compounds are of the following structure:
• L is a linker moiety
• Q is a detectable moiety
• X is O, S, NR] or CHR 2
• Y is H, N 3 , F, ORj, SRi or NHRi
• Z is H, N 3 , F or ORi
• A is H or a functional group that permits the attachment of the nucleic acid label to a nucleic acid
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• the substituents R] and R 2 are independent of one another and are H, alkyl or aryl.
• the heterocyclic group (H c ) is an N4 substituted 4- amino-pyrazolo[3,4-d]pyrimidine and the linking group is an amino alkyl:
• Y is hydrogen or hydroxyl
• Z is hydrogen or hydroxyl
• n is an integer ranging from about 2 to about 10
• A is hydrogen or H 4 O P 3 -
• Q is biotin or carboxyfluorescein
• M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH- wherein m is 1 or 0.
• Y and Z are hydrogen; n is 4; A is H 4 O 9 P 3 -; Q is biotin or 5- or 6-carboxyfluorescein, wherein m is 0.
• the heterocyclic group (H c ) is a l,2,4-triazine-3-one
• the nucleic acid labeling compounds are of the following structure:
• L is a linker moiety
• Q is a detectable moiety
• X is O, S, NR] or CHR
• Y is H, N 3 , F, ORi, SRi or NHRi
• Z is H, N 3 , F or ORj
• A is H or a functional group that permits the attachment of the nucleic acid label to a nucleic acid
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• the substituents Ri and R 2 are independent of one another and are H, alkyl or aryl.
• heterocyclic group (H c ) is a l,2,4-triazine-3-one and the linking group is amino alkyl:
• Y is hydrogen or hydroxyl
• Z is hydrogen or hydroxyl
• n is an integer ranging from about 2 to about 10
• A is hydrogen or H 4 O 9 P -
• Q is biotin or carboxyfluorescein
• M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH-, wherein m is 1 or 0.
• Y and Z are hydroxyl
• n is 4
• A is H 4 O 9 P -
• Q is biotin or 5- or 6-carboxyfluorescein, wherein M is -CO(CH 2 ) 5 NH- and m is 1.
• heterocyclic group (H c ) is a l,2,4-triazine-3,5-dione
• nucleic acid labeling compounds are of the following structure:
• L is a linker moiety
• Q is a detectable moiety
• X is O, S, NR] or CHR 2
• Y is H, N 3 , F, ORj, SR] or NHRi
• Z is H, N 3 , F or ORi
• A is H or a functional group that permits the attachment of the nucleic acid label to a nucleic acid
• M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• the substituents R ⁇ and R 2 are independent of one another and are H, alkyl or aryl.
• the heterocyclic group (H c ) is a l,2,4-triazine-3,5-dione and the linking group is alkenyl alkyl:
• Y is hydrogen or hydroxyl
• Z is hydrogen or hydroxyl
• n is an integer ranging from about 1 to about 10
• R 5 is NR 6 , wherein R 6 is hydrogen, alkyl or aryl
• A is hydrogen or H 4 O 9 P 3 -
• Q is biotin or carboxyfluorescein
• M is -CO(CH 2 ) 5 NH- or
• heterocyclic group (H c ) is a 5-amino-l,2,4-triazine-3- one
• nucleic acid labeling compounds are of the following structure:
• L is a linker moiety; Q is a detectable moiety; X is O, S, NRi or CHR 2 ; Y is H, N 3 , F, ORj, SRi or NHRi; Z is H, N 3 , F or OR]; A is H or a functional group that permits the attachment of the nucleic acid label to a nucleic acid; and, M is a connecting group, wherein m is an integer ranging from 0 to about 3.
• the substituents Ri and R 2 are independent of one another and are H, alkyl or aryl.
• the heterocyclic group (H c ) is a 5-amino-l,2,4-triazine- 3 -one and the linking group is alkenyl alkyl:
• Y is hydrogen or hydroxyl
• Z is hydrogen or hydroxyl
• n is an integer ranging from about 1 to about 10
• R 5 is NR , wherein R ⁇ is hydrogen, alkyl or aryl
• A is hydrogen or H 4 O 9 P -
• Q is biotin or carboxyfluorescein
• M is -CO(CH 2 ) 5 NH- or -CO(CH 2 ) 5 NHCO(CH 2 ) 5 NH-, wherein m is 1 or 0.
• Figure 3 shows a synthetic route to nucleic acid labeling compounds 8a and 8b, in which the heterocyclic group (H c ) is an imidazole and the linker moiety (L) is an amido alkyl.
• the silyl protected imidazole (2) was added to pentofuranose (1) to provide a mixture of carboethoxyimidazole dideoxyriboside isomers (3a-3d). The isomers were separated to afford purified 3c.
• the carboethoxy group of 3c was converted into an amino carboxamide (4) upon treatment with a diamine.
• the terminal amine of 4 was protected to give the trifluoroacetylated product 5.
• the silyl protecting group of 5 was removed, providing the primary alcohol 6.
• Figure 4 shows a synthetic route to C3-labeled 4-aminopyrazolo[3,4-d]pyrimidine ⁇ -D-ribofuranoside triphosphates.
• a protected propargylamine linker was added to nucleoside (9) under palladium catalysis to provide the coupled product (10).
• the primary alcohol of the alkyne substituted nucleoside (10) was phosphorylated, yielding the 5'- triphosphate 11.
• the protected amine of triphosphate 11 was then deprotected, and the resulting primary amine was treated with a reactive biotin or fluorescein derivative to afford, respectively, nucleic acid labeling compounds 12a and 12b.
• Figure 5 shows a synthetic route to pyrazolopyrimidine nucleotides.
• a chloropyrazolopyrimidine (13) was added to pentofuranose 1 to provide adduct 14 as a mixture of anomers.
• a diamine was added to compound 14, affording a mixture of primary amines (15).
• the primary amines (15) were protected and chromatographically separated to yield the pure ⁇ -anomer 16.
• the silyl group of 16 was removed and the resulting primary alcohol was phosphorylated to provide triphosphate 17.
• the trifluoroacetyl group of 17 was removed and the deprotected amine was treated with a reactive biotin or carboxyfluorescein derivative giving, respectively, nucleic acid labeling compounds 18a- 18d.
• Figure 6 shows a synthetic route to N4-labeled l,2,4-triazine-3-one ⁇ -D- ribofuranoside triphosphates.
• l,2,4-Triazine-3,5-dione ribonucleoside 19 was converted into the triazole nucleoside 20 upon treatment with triazole and phosphorous trichloride.
• Addition of a diamine to 20 provided aminoalkyl nucleoside 21.
• the primary amine of 21 was protected, affording trifluoroacetamide 22.
• the primary alcohol of 22 was phosphorylated, and the protected amine was deprotected and reacted with a reactive biotin or carboxyfluorescein derivative, giving, respectively, nucleic acid labeling compounds 23a and 23b.
• Figure 7 shows a synthetic route to C5-labeled l,2,4-triazine-3,5-dione riboside phosphates.
• Aldehyde 24 is reacted with ylide 25 to provide the phthalimide protected allylamine 26.
• Compound 26 is coupled with pentofuranoside 27, yielding nucleoside 28.
• the phthalimide group of 28 is removed upon treatment with hydrazine to afford primary amine 29.
• Amine 29 is protected as amide 30.
• Amide 30 is phosphorylated, deprotected and treated with a reactive derivative of biotin or carboxyfluorescein, giving, respectively, nucleic acid labeling compounds 31a and 31b.
• Figure 8 shows a synthetic route to C5-labeled 5-amino-l,2,4-triazine-3-one riboside triphosphates.
• Compound 28 is converted into the amino-l,3-6-triazine compound 32 upon treatment with a chlorinating agent and ammonia.
• the phthalimide group of 32 is removed upon treatment with hydrazine, and the resulting primary amine is protected to provide 33.
• Compound 33 is phosphorylated, deprotected and treated with a reactive derivative of biotin or carboxyfluorescein, giving, respectively, nucleic acid labeling compounds 34a and 34b.
• Nucleic acids can be isolated from a biological sample or synthesized, on a solid support or in solution for example, according to methods known to those of skill in the art. As used herein, there is no limitation on the length or source of the nucleic acid used in a labeling process. Exemplary methods of nucleic acid isolation and purification are described in Theory and Nucleic Acid Preparation. In Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes; P. Tijssen, Ed.; Part I; Elsevier: N.Y., 1993. A preferred method of isolation involves an acid guanidinium-phenol-chloroform extraction followed by oligo dT column chromotography or (dT)n magnetic bead use.
• nucleic acids are increased in quantity through amplification.
• Suitable amplification methods include, but are not limited to, the following examples: polymerase chain reaction (PCR) (Innis, et al. PCR Protocols. A guide to Methods and Application; Academic Press: San Diego, 1990); ligase chain reaction (LCR) (Wu and Wallace. Genomics 1989, 4, 560; Landgren, et al. Science 1988, 241, 1077; and Barringer, et al. Gene 1990, 89, 117); transcription amplification (Kwoh et al. Proc. Natl. Acad. Sci.
• PCR polymerase chain reaction
• LCR ligase chain reaction
• the nucleic acid labeling compound can be incorporated into a nucleic acid using a number of methods. For example, it can be directly attached to an original nucleic acid sample (e.g., MRNA, polyA mRNA, cDNA) or to an amplification product. Methods of attaching a labeling compound to a nucleic acid include, without limitation, nick translation, 3 -end-labeling, ligation, in vitro transcription (IVT) or random priming. Where the nucleic acid is an RNA, a labeled riboligonucleotide is ligated, for example, using an RNA ligase such asT4 RNA Ligase. In The Enzymes; Uhlenbeck and Greensport, Eds.; Vol.
• Terminal transferase is used to add deoxy-, dideoxy- or ribonucleoside triphosphates (dNTPs, ddNTPs or NTPs), for example, where the nucleic acid is single stranded DNA.
• the labeling compound can also be incorporated at an internal position of a nucleic acid.
• PCR in the presence of a labeling compound provides an internally labeled amplification product.
• IVT in the presence of a labeling compound can provide an internally labeled nucleic acid.
• the nucleic acid to which the labeling compound is attached can be detected after hybridization with a nucleic acid probe.
• the probe can be labeled, depending upon the experimental scheme preferred by the user.
• the probe is a nucleic acid, or a modified nucleic acid, that is either attached to a solid support or is in solution. It is complementary in structure to the labeled nucleic acid with which it hybridizes.
• the solid support is of any suitable material, including polystyrene based beads and glass chips.
• the probe or target nucleic acid is attached to a glass chip, such as a GeneChip ® product (Affymetrix, Inc., Santa Clara, CA). See International Publication Nos.
• nucleic acid labeling compound Because probe hybridization is often a step in the detection of a nucleic acid, the nucleic acid labeling compound must be of a structure that does not substantially interfere with that process. The steric and electronic nature of the labeling compound, therefore, is compatible with the binding of the attached nucleic acid to a complementary structure.
• Reagents were purchased from Aldrich Chemical Company (Milwaukee, WI) in the highest available purity. All listed solvents were anhydrous. Intermediates were characterized by ⁇ NMR and mass spectrometry.
• the isomeric products were purified and separated by flash chromatography (silica gel, EtOAc-hexane), in 52% total yield.
• the ⁇ -Nl isomer (2.2g; 18% yield), was identified by 1H-NMR chemical shift and NOE data (see, Pochet, S, et. al, Bioorg. Med. Chem. Lett., 1995, 5, 1679).
• Nucleoside 6 was converted to a 5 '-triphosphate, deprotected, reacted with biotin- NH(CH 2 ) 5 CO-NHS or 5-carboxyfluorescein-NHS and purified according to procedures reported elsewhere (see, Prober, J.M., et al., 1988, PCT 0 252 683 A2) to give the labeled nucleotides 8a,b in >95% purity by HPLC, 31 P-NMR.
• the nucleoside was converted to a 5 '-triphosphate (11), deprotected, reacted with oxysuccinimidyl-(N-biotinoyl-6-amino)hexanoate, or oxysuccinimidyl-(N-(fluorescein-5- carboxyl)-6-amino)hexanoate, and purified according to procedures reported elsewhere (Prober, J.M., et al, 1988, PCT 0 252 683 A2.) to give the biotin- and fluorescein-labeled nucleotides (12a, 12b) in >95% purity.
• the nucleoside was converted to the triphosphate using the Eckstein phosphorylation procedure (Ludwig, J. L. ; Eckstein, F. J. Org. Chem. 1989, 54, 631-635) followed by HPLC purification on a ResourceQ anion exchange column (buffer A is 20 mM Tri pH8, 20% CH 3 CN and buffer B is 20 mM Tris pH8, 1 M NaCl, 20 % CH3CN).
• the nucleoside was converted to a 5 '-triphosphate, deprotected, reacted with oxysuccinimidyl-(N-biotinoyl-6-amino)hexanoate, or oxysuccinimidyl-(N-(fluorescein-5- carboxyl)-6-amino)hexanoate, and purified according to procedures reported elsewhere (Prober, J.M., et al., 1988, PCT 0 252 683 A2.) to give the biotin- and fluorescein-labeled nucleotides (23a, 23b) in >95% purity.
• ⁇ -ribonucleoside 28 is deprotected with anhydrous hydrazine in THF to provide allylamine 29. Reaction of primary amine 29 with trifluoroacetylimidazole in THF affords the protected amine 30.
• Nucleoside 30 is converted to a 5 '-triphosphate, deprotected, reacted with oxysuccinimidyl-(N-biotinoyl-6-amino)hexanoate or oxysuccinimidyl-(N-(fluorescein-5- carboxy)-6-amino)hexanoate and purified according to procedures reported elsewhere (Prober, J.M., et al. 1988, PCT 0 252 683 A2), giving, respectively, the biotin- and fluorescein-labeled nucleotides 31a and 31b.
• Nucleoside 33 is converted to a 5'- triphosphate, deprotected, reacted with oxysuccinimidyl-(N-biotinoyl-6-amino)hexanoate or oxysuccinimidyl-(N-(fluorescein-5-carboxy)-6-amino)hexanoate and purified according to procedures reported elsewhere (Prober, J.M., et al. 1988, PCT 0 252 683 A2), giving, respectively, the biotin- and fluorescein-labeled nucleotides 34a and 34b.
• IX buffer, pH 7.5 (Promega) Procedure incubate lhr. at 37 °C, then for 10 min. at 70 ⁇ C , followed by the addition of EDTA (2 mM final concentration) in a volume of 50 uL
• the incorporation efficiency is expressed as the fraction of oligonucleotide that is labeled. This number is determined by dividing the peak area measured at 260 nm absorbance of the labeled oligonucleotide by the sum of the peak areas of the unlabeled and labeled oligonucleotide. ( The retention time of fluorescein-labeled dTi6 is on the order of 2 to 3 min. longer than the unlabeled dTi 6.) The error in this type of assay is about 10%.
• the sample DNA used in these experiments was the plasmid "p53mut248.”
• Labeling reactions were carried out using both the standard amount of TdT enzyme specified in the assay protocol (25 U) and with 100 U of enzyme. After labeling, Fluorescein-labeled targets were hybridized to the arrays and scanned directly.
• Figure 9 shows comparisons of the observed hybridization fluorescence intensities for the 1300 bases called in the "Unit-2" part of the chip.
• intensities for the Fluorescein-ddlTP (8b) labeled targets are plotted against those for the standard Fluorescein-N6-ddATP labeled targets (control), both at 25 U of TdT.
• the observed slope of -0.75 indicates that the labeling efficiency of 8b was about 75% of that of Fluorescein- N6-ddATP under these conditions.
• the same comparison is made, except that 100 U of TdT was used in the 8b labeling reaction.
• the slope of -1.1 indicates equivalent or slightly better labeling than the standard Fluorescein-N6-ddATP/25 U control reaction.
• Figure 10 shows comparisons of the observed hybridization fluorescence intensities for the 1300 bases called in the "Unit-2" part of the chip.
• the observed slope of -0.3 indicates that the labeling efficiency withBiotin-(M) 2 -ddAPPTP (18c) was about 30% of that of Biotin-M-N6-ddATP under these conditions.
• Figure 11 shows comparisons of the observed hybridization fluorescence intensities for the 1300 bases called in the "Unit-2" part of the chip.
• the observed slope of -0.4 indicates that the labeling efficiency with 8a was about 40% of that of Biotin-M-N6-ddATP under these conditions.
• the same comparison is made, except that 100 U of TdT was used in the 8a labeling reaction.
• FIG. 12 shows a comparison of the overall re-sequencing (base-calling) accuracy, for both strands, obtained using Fluorescein-ddlTP labeled targets at both 25 U and 100 U of TdT, as well as the standard Fluorescein-N6-ddATP/25 U TdT labeled "control" targets.
• Figure 13 shows a similar comparison for the targets labeled with biotin-M-ddlTP (8a; referred to as Biotin-ddlTP in Fig. 13) and biotin-M-N6-ddATP "control," followed by PE- SA staining.
• Figure 14 shows a comparison of re-sequencing accuracy using Biotin-(M) 2 - ddAPPTP/100 U TdT and Biotin-M-N6-ddATP/25 U TdT.
• Example 9 The performance of the biotin-labeled imidazolecarboxamide and 4- aminopyrazolo[3,4- ]pyrimidine nucleotides ("biotin-M-ITP” (8a) and “biotin-(M) - APPTP” (18c)) was evaluated using a single-nucleotide polymorphism genotyping GeneChip ® chip array. Published protocols (D.G. Wang, et al., 1998, Science 280: 1077-

Priority Applications (6)

Applications Claiming Priority (2)

Publications (3)

Family

ID=22425958

Family Applications (1)

Country Status (8)

Cited By (21)

Families Citing this family (44)

Citations (7)

Family Cites Families (65)

• 1998
  • 1998-07-31 US US09/126,645 patent/US20010018514A1/en not_active Abandoned
• 1999
  • 1999-07-20 DE DE69925624T patent/DE69925624T2/de not_active Expired - Lifetime
  • 1999-07-20 WO PCT/US1999/012390 patent/WO2000006771A2/en active IP Right Grant
  • 1999-07-20 EP EP05011696A patent/EP1589025A3/en not_active Withdrawn
  • 1999-07-20 AU AU52035/99A patent/AU5203599A/en not_active Abandoned
  • 1999-07-20 CA CA002339016A patent/CA2339016A1/en not_active Abandoned
  • 1999-07-20 AT AT99937150T patent/ATE296833T1/de not_active IP Right Cessation
  • 1999-07-20 JP JP2000562553A patent/JP2002521495A/ja active Pending
  • 1999-07-20 EP EP99937150A patent/EP1124838B1/en not_active Expired - Lifetime
• 2001
  • 2001-02-09 US US09/780,574 patent/US6596856B2/en not_active Expired - Lifetime
• 2003
  • 2003-06-02 US US10/452,375 patent/US6844433B2/en not_active Expired - Lifetime
  • 2003-06-02 US US10/452,519 patent/US7179905B2/en not_active Expired - Lifetime
• 2005
  • 2005-01-18 US US11/037,065 patent/US7491818B2/en not_active Expired - Fee Related
• 2006
  • 2006-03-20 JP JP2006077729A patent/JP2006258818A/ja active Pending

Patent Citations (7)

Non-Patent Citations (24)

Also Published As

Similar Documents

Legal Events